Overview

* iRhythm Q2 2025 revenue rises 26.1% yr/yr, beating analyst expectations

* Gross margin improves to 71.2%, reflecting operational efficiencies

* Co partners with Lucem Health to enhance arrhythmia detection

Outlook

* iRhythm projects 2025 revenue between $720 mln and $730 mln

* Company expects 2025 adjusted EBITDA margin of 8.0% to 8.5%

Result Drivers

* CORE MONITORING - Growth driven by demand in core long-term continuous monitoring business

* ZIO AT DEMAND - Continued market penetration of Zio AT across major health systems

* INTERNATIONAL MARKETS - Contribution from international markets supports revenue growth

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $186.70 $173.90

Revenue mln mln (12

Analysts

)

Q2 -$10.20

Adjusted mln

Net

Income

Q2 Net -$14.20

Income mln

Q2 Gross 71.2%

Margin

Q2 Gross $132.90

Profit mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

* Wall Street's median 12-month price target for iRhythm Technologies Inc ( IRTC ) is $147.00, about 4.7% above its July 30 closing price of $140.08

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)